In this Special Issue we bring together papers demonstrating the need for both detailed genomic and phenotypic studies to aid our scientific and clinical understanding of neurogenetic disorders. Genomic techniques such as genome and exome sequencing are vital tools for diagnosing rare neurogenetic disorders and identifying novel causal genes [1,2]. In this Special Issue, Gardner and colleagues [3] utilise genomic techniques to identify a series of individuals with brain malformations due to the recurrent TUBA1A p.Arg2His variant. This paper also describes the detailed phenotyping required to aid in the interpretation of novel genomic variants. Variants in GBA1, the gene causing Gaucher Disease (GD), are associated with an increased risk of Parkinson’s Disease (PD) [4,5]. Gatto and colleagues review this important area and describe how simple clinical observations helped begin the identification of this important risk factor for PD [6]. Genomic techniques are crucial for the diagnosis of neurogenetic disorders [7]. Garcia and Bustos [8] review the impact of such techniques for both the diagnosis of neurogenetic diseases and increasing our scientific understanding of these disorders. It is only through the co-development of both novel genomic and phenotypic assessments that we will be able to fully understand the pathogenesis of neurogenetic disorders and identify novel treatments.
Conflicts of Interest
The author declares no conflict of interest.
References
- 1.Hempel A., Pagnamenta A.T., Blyth M., Mansour S., McConnell V., Kou I., Ikegawa S., Tsurusaki Y., Matsumoto N., Lo-Castro A., et al. Deletions and de novo mutations of SOX11 are associated with a neurodevelopmental disorder with features of Coffin-Siris syndrome. J. Med. Genet. 2016;53:152–162. doi: 10.1136/jmedgenet-2015-103393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Blanchet P., Bebin M., Bruet S., Cooper G.M., Thompson M.L., Duban-Bedu B., Gerard B., Piton A., Suckno S., Deshpande C., et al. MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamus. Plos Genet. 2017;13:e1006957. doi: 10.1371/journal.pgen.1006957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Gardner J.F., Cushion T.D., Niotakis G., Olson H.E., Grant P.E., Scott R.H., Stoodley N., Cohen J.S., Naidu S., Attie-Bitach T., Bonnières M., Boutaud L., Encha-Razavi F., Palmer-Smith S.M., Mugalaasi H., Mullins J.G.L., Pilz D.T., Fry A.E. Clinical and Functional Characterization of the Recurrent TUBA1A p.(Arg2His) Mutation. Brain Sci. 2018;8:145. doi: 10.3390/brainsci8080145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.McNeill A., Duran R., Proukakis C., Bras J., Hughes D., Mehta A., Hardy J., Wood N.W., Wood A.H.V. Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov. Disord. 2012;27:526–532. doi: 10.1002/mds.24945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.McNeill A., Duran R., Hughes D.A., Mehta A., Schapira A.H. A clinical and family history study of Parkinson’s disease in heterozygous glucocerebrosidase mutation carriers. J. Neurol. Neurosurg. Psych. 2012;83:853–854. doi: 10.1136/jnnp-2012-302402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Gatto E.M., Da Prat G., Etcheverry J.L., Drelichman G., Cesarini M. Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency. Brain Sci. 2019;9:30. doi: 10.3390/brainsci9020030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Majewski J., Schwartzentruber J., Lalonde E., Montpetit A., Jabado N. What can exome sequencing do for you? J. Med. Genet. 2011;48:580–589. doi: 10.1136/jmedgenet-2011-100223. [DOI] [PubMed] [Google Scholar]
- 8.García J.-C., Bustos R.-H. The Genetic Diagnosis of Neurodegenerative Diseases and Therapeutic Perspectives. Brain Sci. 2018;8:222. doi: 10.3390/brainsci8120222. [DOI] [PMC free article] [PubMed] [Google Scholar]